DISTRIBUTION OF INTRARETINAL EXUDATES IN DIABETIC MACULAR EDEMA DURING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY OBSERVED BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY AND FUNDUS PHOTOGRAPHY

Purpose: To evaluate changes in the distribution and morphology of intraretinal microexudates and hard exudates (HEs) during intravitreal anti-vascular endothelial growth factor therapy in patients with persistent diabetic macular edema. Methods: Twenty-four patients with persistent diabetic macular edema after photocoagulation were investigated in this prospective cohort study. Each eye was assigned to a loading dose of three anti-vascular endothelial growth factor treatments at monthly intervals. Additional single treatments were performed if diabetic macular edema persisted or recurred. Intraretinal exudates were analyzed over 6 months using spectral domain optical coherence tomography (SD-OCT) and fundus photography. Results: Before treatment, microexudates were detected by SD-OCT as hyperreflective foci in 24 eyes, whereas HEs were seen in 22 eyes. During therapy, HE increased significantly in number and size. This was accompanied by accumulation of microexudates in the outer retina. Enlargement of hyperreflective structures in SD-OCT was accompanied by enlargement of HE at corresponding fundus locations. A rapid reduction in diabetic macular edema was seen in all patients, but to varying degrees. Patients with hemoglobin A1c levels <7% and serum cholesterol <200 mg/dL formed fewer HEs and featured more edema reduction and visual acuity gain. Conclusion: Diabetic macular edema reduction during intravitreal anti-vascular endothelial growth factor therapy was accompanied by dynamic rearrangement of intraretinal exudates at corresponding locations in fundus photography and SD-OCT. Intraretinal aggregates of microexudates detectable as hyperreflective foci by SD-OCT may compose and precede HE before they become clinically visible.

[1]  P. Campochiaro,et al.  Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. , 2013, JAMA ophthalmology.

[2]  T. Peto,et al.  A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. , 2012, Archives of ophthalmology.

[3]  Michael Larsen,et al.  Local retinal sensitivity in relation to specific retinopathy lesions in diabetic macular oedema , 2012, Acta ophthalmologica.

[4]  U. Schmidt-Erfurth,et al.  Polarization sensitive optical coherence tomography in the human eye , 2011, Progress in Retinal and Eye Research.

[5]  Nagahisa Yoshimura,et al.  Optical coherence tomographic evaluation of foveal hard exudates in patients with diabetic maculopathy accompanying macular detachment. , 2010, Ophthalmology.

[6]  Y. Iwamoto,et al.  Association of systemic health and functional outcomes with changes in hard exudates associated with clinically significant macular oedema over the natural course of the disease , 2010, British Journal of Ophthalmology.

[7]  Reginald Birngruber,et al.  Selective retina therapy (SRT) for clinically significant diabetic macular edema , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[8]  Matthias Bolz,et al.  Effect of retinal photocoagulation on intraretinal lipid exudates in diabetic macular edema documented by optical coherence tomography. , 2010, Ophthalmology.

[9]  M. Lövestam-Adrian,et al.  Using multifocal electroretinography hard exudates affect macular function in eyes with diabetic retinopathy , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[10]  Matthias Bolz,et al.  Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. , 2009, Ophthalmology.

[11]  Thomas Martini Jørgensen,et al.  Enhanced optical coherence patterns of diabetic macular oedema and their correlation with the pathophysiology. , 2008, Acta ophthalmologica Scandinavica.

[12]  M. Larsen,et al.  Progression of diabetic macular edema: correlation with blood retinal barrier permeability, retinal thickness, and retinal vessel diameter. , 2007, Investigative ophthalmology & visual science.

[13]  P. Campochiaro,et al.  Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. , 2006, American journal of ophthalmology.

[14]  Quan Dong Nguyen,et al.  Persistent diabetic macular edema is associated with elevated hemoglobin A1c. , 2005, American journal of ophthalmology.

[15]  J. Manson,et al.  A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. , 2004, Diabetes.

[16]  Vishali Gupta,et al.  Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. , 2004, American journal of ophthalmology.

[17]  D. Lackland,et al.  Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. , 2004, Investigative ophthalmology & visual science.

[18]  F. Ferris,et al.  Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group. , 1997, Archives of ophthalmology.

[19]  B. Hoogwerf,et al.  Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. , 1996, Archives of ophthalmology.

[20]  G. Hommel.  A stagewise rejective multiple test procedure based on a modified Bonferroni test , 1988 .

[21]  Marco A Zarbin,et al.  Diabetic macular edema: pathogenesis and treatment. , 2009, Survey of ophthalmology.

[22]  Michael F. Marmor,et al.  Mechanisms of fluid accumulation in retinal edema , 2004, Documenta Ophthalmologica.

[23]  R. Klein,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. , 1995, Ophthalmology.